A new study has identified a critical biological transition in the brain’s immune cells that may determine whether Alzheimer’s disease pathology leads to dementia. Researchers from VIB, KU Leuven, the UK Dementia Research Institute and Muna Therapeutics found that changes in microglia, the brain’s resident immune cells, could represent an important target for future Alzheimer’s therapies.

Key takeaways

  • Researchers identified distinct cellular programs and immune cell states in brain tissue from older adults with and without cognitive decline.
  • The study included cognitively healthy centenarians, providing insights into resilience against Alzheimer’s pathology.
  • Changes in microglia may represent a tipping point that determines whether Alzheimer’s pathology progresses to dementia.
  • The findings were published in Nature Medicine and suggest new targets for Alzheimer’s therapies.

What the study found

The research team analyzed brain tissue from older adults who had experienced cognitive decline, those who remained cognitively healthy, and a group of cognitively healthy centenarians. By comparing these groups, they uncovered distinct cellular programs and immune cell states associated with both disease progression and resilience.

The study focused on microglia, the brain’s primary immune cells. These cells normally help clear debris and maintain brain health. However, the researchers found that in people who developed dementia, microglia underwent a key transition that shifted them from a protective state to a harmful one. This transition appeared to be a tipping point that allowed Alzheimer’s pathology to cause cognitive decline.

Why microglia matter in Alzheimer’s

Microglia play a complex role in Alzheimer’s disease. In healthy brains, they help remove amyloid plaques and other toxic proteins. But as the disease progresses, microglia can become chronically activated, releasing inflammatory molecules that damage neurons.

The new study suggests that this transition from protective to harmful microglia is not inevitable. By studying centenarians who remained cognitively healthy despite having Alzheimer’s pathology in their brains, the researchers identified cellular programs that may protect against dementia. These resilient individuals appeared to maintain microglia in a more protective state.

Implications for future treatments

The findings open new avenues for Alzheimer’s therapies. Instead of targeting amyloid plaques or tau tangles directly, future treatments could focus on maintaining microglia in their protective state or preventing the harmful transition.

According to the original report from Medical Xpress, the researchers believe that understanding these cellular programs could lead to biomarkers that identify people at risk of tipping into dementia. It could also help develop drugs that keep microglia healthy.

Frequently Asked Questions

What are microglia?

Microglia are immune cells that reside in the brain. They act as the brain’s first line of defense, clearing away debris, dead cells, and harmful proteins. They also help maintain healthy connections between neurons.

How does this study differ from previous Alzheimer’s research?

Most Alzheimer’s research has focused on amyloid plaques and tau tangles, the hallmark proteins of the disease. This study shifts attention to the brain’s immune system and identifies a specific transition point in microglia that may determine whether pathology leads to dementia.

Could this lead to a test for Alzheimer’s risk?

Possibly. The researchers suggest that the cellular programs they identified could lead to biomarkers that help identify people at risk of transitioning from Alzheimer’s pathology to dementia. However, more research is needed before such tests become available.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.